Raising the bar for using surrogate endpoints in drug regulation and health technology assessment

Raising the bar for using surrogate endpoints in drug regulation and health technology assessment Analysis Raising the bar for using surrogate endpoints in drug regulation and health technology assessment BMJ 2021 ; 374 doi: https://doi.org/10.1136/bmj.n2191 (Published 16 September 2021) Cite this as: BMJ 2021;374:n2191 Dalia Dawoud , senior scientific adviser 1 , Huseyin Naci , associate professor of health policy 2 , Oriana Ciani , associate professor of practice 3 4 , Sylwia Bujkiewicz , professor of biostatistics 5 1 Science, Evidence and Analytics Directorate, Science Policy and Research Programme, National Institute for Health and Care Excellence, London, UK 2 …

Read the source article at The BMJ
2021-09-16 01:00:00